Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine

Schizophrenia Research

Volumn 96, Issue 1-3, 2007, Pages 146-155

  Voruganti, L P ^a   Awad, A G ^b   Parker, G ^a   Forrest, C ^a   Usmani, Y ^a   Fernando, M L D ^c   Senthilal, S ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Cognition; Olanzapine; Outcomes; Quality of life; Quetiapine; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLONAZEPAM; CLOPENTHIXOL; DOPAMINE RECEPTOR; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LITHIUM; LORAZEPAM; LOXAPINE; OLANZAPINE; PERPHENAZINE; PIPOTIAZINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRIFLUOPERAZINE; VALPROATE SEMISODIUM;

ADULT; AGITATION; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; COMMUNITY; COMPUTER ASSISTED COGNITIVE TEST BATTERY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG ATTITUDE INVENTORY; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HEALTH CARE QUALITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC TEST; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SICKNESS IMPACT PROFILE; SIDE EFFECT; SINGLE BLIND PROCEDURE; SLEEP DISORDER; SOCIAL INTERACTION; SYMPTOM; TASK PERFORMANCE; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; AWARENESS; BENZODIAZEPINES; COGNITION; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SINGLE-BLIND METHOD; SPACE PERCEPTION; TREATMENT OUTCOME; VISUAL PERCEPTION;

EID: 34848914326     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2007.08.002     Document Type: Article

References (50)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. fourth edition (1994), American Psychiatric Association, Washington, DC
2. Awad A.G. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bulletin 19 3 (1993) 609-618
3. Awad A.G., and Voruganti L.N. Impact of atypical antipsychotics on quality of life in patients with schizophrenia. CNS Drugs 18 13 (2004) 877-893
4. Awad A.G., and Voruganti L.P. Body weight, image and self-esteem evaluation questionnaire: development and validation of a new scale. Schizophr. Res. 70 1 (2004) 63-67
5. Awad A.G., and Voruganti L.P. Antipsychotic medications, schizophrenia and the issue of quality of life. In: Ritsner M.S., and Awad A.G. (Eds). Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders: New Perspectives on Research and Treatment (2007), Springer
6. Awad A.G., Lapierre Y.D., Angus C., and Rylander A. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. J. Psychiatry Neurosci. 22 4 (1997) 244-248
7. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989) 672-676
8. Bergner M., Bobbit R., Carter W., and Gilson B. The sickness impact profile: development and final revision of a health status measure. Med. Care 29 (1981) 787-806
9. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., Nuechterlein K.H., Laughren T., Levin R., Stover E., Fenton W., and Marder S.R. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 31 1 (2005) 5-19
10. Chwastiak L.A., Rosenheck R.A., McEvoy J.P., Keefe R.S., Swartz M.S., and Lieberman J.A. Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. Psychiatr. Serv. 57 8 (2006) 1102-1109
11. Endicott J., Spitzer R.L., Fleiss J.L., and Cohen J. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry 33 (1976) 766-771
12. Fleming K., Thyrum P., Yeh C., et al. Cognitive improvements in psychotic subjects treated with Seroquel (quetiapine fumarate): an exploratory study. J. Clin. Psychopharmacol. 21 5 (2001) 527-528
13. Good K.P., Kiss I., Buiteman H., et al. Improvement in cognitive functioning in patients with first-episode psychosis during treatment with quetiapine: an interim analysis. Br. J. Psychiatry 181 suppl. 43 (2002) s45-s49
14. Green M.F., Kern R.S., Braff D.L., and Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 26 (2000) 119-136
15. Green M.F., Kern R.S., and Heaton R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res. 72 1 (2004) 41-51
16. Guy W. ECDEU Assessment Manual for Psychopharmacology (1976), US Department of Health, Education & Welfare, Washington, DC revised
17. Harvey P.D. Cognitive and functional effects of atypical antipsychotic medications. J. Clin. Psychiatry 67 10 (2006) e13
18. Harvey P.D., and McClure M.M. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs 66 11 (2006) 1465-1473
19. Heinrichs R.W., and Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12 3 (1998) 426-445
20. Hofer A., Baumgartner S., Bodner T., Edlinger M., Hummer M., Kemmler G., Rettenbacher M.A., and Fleischhacker W.W. Patient outcomes in schizophrenia II: the impact of cognition. Eur. Psychiatr. 20 5-6 (2005) 395-402
21. Horacek J., Bubenikova-Valesova V., Kopecek M., Palenicek T., Dockery C., Mohr P., and Hoschl C. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 20 5 (2006) 389-409
22. Jarskog L.F., and Lieberman J.A. Neuroprotection in schizophrenia. J. Clin. Psychiatry 67 9 (2006) e09
23. 2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am. J. Psychiatry 158 (2001) 360-369
24. Kapur S., Remington G., Zipursky R.B., et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 57 10 (1995) PL103-PL107
25. Kapur S., Zipursky R., Jones C., Shammi C.S., Remington G., and Seeman P. A positron emission tomography study of quetiapine in schizophrenia. Arch. Gen. Psychiatry 57 (2000) 553-559
26. Kasper S., and Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin. Pharmacother. 1 4 (2000) 783-801
27. Kay S., Fiszbein A., and Opler L. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261
28. Keefe R.S., Poe M., Walker T.M., Kang J.W., and Harvey P.D. The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity. Am. J. Psychiatry 163 3 (2006) 426-432
29. Keefe R.S.E., Bilder R.M., Davis S.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 64 (2007) 633-647
30. Lang U.E., Jockers-Scherubl M.C., and Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. J. Neural Transm. 111 3 (2004) 387-411
31. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., and Hsiao J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353 (2005) 1209-1223
32. Lindenmayer J.P., Khan A., Iskander A., Abad M.T., and Parker B. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J. Clin. Psychiatry 68 3 (2007) 368-379
33. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU Side Effect Rating Scale - a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 334 (1987) 1-100
34. Lindstrom E., Lewander T., Malm U., Malt U.F., Lublin H., and Ahlfors U.G. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord. J. Psychiatry 55 Suppl 44 (2001) 5-69
35. Marder S.R. Drug initiatives to improve cognitive function. J. Clin. Psychiatry 67 Suppl 9 (2006) 31-35
36. Purdon S.E., Malla A., Labelle A., and Lit W. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J. Psychiatry Neurosci. 26 2 (2001) 137-149
37. Salkever D., Slade E., and Karakus M. Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients: estimates from a prospective naturalistic study. PharmacoEconomics 24 2 (2006) 123-139
38. Sax K.W., Strakowski S.M., and Keck Jr. P.E. Attentional improvement following quetiapine fumarate treatment in schizophrenia. Schizophr. Res. 33 3 (1998) 151-155
39. 2 receptors yet occupy high levels of these receptors. Mol. Psychiatry 3 (1998) 123-134
40. Simpson G., and Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 212 (1970) 11-19 (suppl)
41. Spaulding W., Hargrove S., Crinean W., and Martin T. A microcomputer based laboratory for psychopathology research in rural settings. Behav. Res. Meth. Instrum. 13 (1981) 616-623
42. Stip E., Caron J., Renaud S., Pampoulova T., and Lecomte Y. Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia. Compr. Psychiatry 44 4 (2003) 331-340
43. Stip E., Chouinard S., and Boulay L.J. On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 29 2 (2005) 219-232
44. The expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26 11 (2003) 3160-3167
45. Velligan D.I., Prihoda T.J., Sui D., Ritch J.L., Maples N., and Miller A.L. The effectiveness of quetiapine versus conventional antipsychotics in improving cognitive and functional outcomes in standard treatment settings. J. Clin. Psychiatry 64 5 (2003) 524-531
46. Voruganti L.N., and Awad A.G. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr. Res. 56 1-2 (2002) 37-46
47. Voruganti L.P., Heslegrave R., and Awad A.G. Neuro-cognitive Correlates of Positive and Negative Schizophrenic Syndromes. Can. J. Psychiatry 42 (1997) 1066-1071
48. Voruganti L.P., Cortese L., Ouyewumi L., Cernovsky J., Zirul S., and Awad A. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr. Res. 57 (2002) 201-208
49. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr. Res. 89 1-3 (2007) 211-224
50. Yulug B., Yildiz A., Hudaoglu O., Kilic E., Cam E., and Schabitz W.R. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. Brain Res. Bull. 71 1-3 (2006) 296-300